

Resource Summary Report

Generated by [NIF](#) on Aug 30, 2026

NOD-scid IL2R³null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)

RRID:BCBC_4142

Type: Organism

Proper Citation

RRID:BCBC_4142

Organism Information

URL:

Proper Citation: RRID:BCBC_4142

Species: Mus musculus

Phenotype: Diabetes mellitus

Catalog Number: 4142

Background: TM

Database: BCBC, Beta Cell Biology Consortium

Database Abbreviation: BCBC

Organism Name: NOD-scid IL2R³null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)

Record Creation Time: 20230226T042341+0000

Record Last Update: 20260829T181703+0000

Ratings and Alerts

No rating or validation information has been found for NOD-scid IL2R³null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ).

No alerts have been found for NOD-scid IL2R³null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ).

Data and Source Information

Source: [Integrated Animals](#)

Source Database: BCBC, Beta Cell Biology Consortium

Usage and Citation Metrics

We found 283 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Pillarisetti K, et al. (2026) Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. *Blood*, 147(8), 834.

Schoonbeek MC, et al. (2026) Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology. *NPJ precision oncology*, 10(1).

Rosenthal KJ, et al. (2026) AKAP2 is required for assembly of cytoskeletal signaling complexes that promote growth and metastasis of triple-negative breast cancer. *The Journal of biological chemistry*, 302(4), 111329.

Abd El-Salam M, et al. (2026) Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathway. *Translational oncology*, 67, 102753.

Aggarwal D, et al. (2026) Patient-derived organoid xenografts reveal the multifaceted role of the lncRNA MALAT1 in breast cancer progression. *bioRxiv : the preprint server for biology*.

Zong L, et al. (2026) Targeting the HERV-K102 envelope elicits pyroptosis and represents a novel therapeutic strategy for acute myeloid leukemia. *Blood research*, 61(1).

Li X, et al. (2026) CISAT, a CoPP-Induced lncRNA, Improves Cardiac Mesenchymal Progenitor Cell Survival and Myocardial Repair via SFPQ/NRF2/p38 Redox Regulation. *Cells*, 15(6).

Hoffmann A, et al. (2026) Animal-origin-free method for generating blood vessel organoids. *Scientific reports*, 16(1).

Lattke M, et al. (2026) Single-cell atlas of the developing Down syndrome brain cortex. *Nature medicine*, 32(3), 1061.

Xu Y, et al. (2026) NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress. *The Journal of clinical investigation*, 136(1).

Suresh V, et al. (2026) Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma. *EMBO molecular medicine*, 18(2), 646.

Elrod R, et al. (2026) Intraperitoneal G-CSF Stimulation Achieves Human-like Neutrophil Levels in NSG Mice Without Inducing Systemic Inflammation. *International journal of*

molecular sciences, 27(11).

Monavarian M, et al. (2026) Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition. JCI insight, 11(4).

Serrano A, et al. (2026) Genetic barcoding uncovers the clonal makeup of solid and liquid biopsies and their ability to capture intra-tumoral heterogeneity. Molecular systems biology, 22(5), 659.

Wang SZ, et al. (2026) Lipocalin 2 orchestrates resistance to ferroptosis via AXL. Cell reports, 45(3), 116965.

Heinze S, et al. (2026) A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity. Molecular therapy. Oncology, 34(1), 201127.

Flaherty RL, et al. (2026) LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma. Cancer research, 86(10), 2487.

Mitra A, et al. (2026) Rhabdoid tumors as a novel target for PSMA-directed CAR T cell therapy. Molecular therapy. Oncology, 34(1), 201125.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Leitão-Castro J, et al. (2026) Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids. Frontiers in bioengineering and biotechnology, 14, 1735980.